Journal
CURRENT OPINION IN ONCOLOGY
Volume 21, Issue 2, Pages 162-170Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0b013e328324bc04
Keywords
allogeneic; autologous; multiple myeloma; stem cell transplantation
Categories
Funding
- NATIONAL CANCER INSTITUTE [K12CA090628] Funding Source: NIH RePORTER
- NCI NIH HHS [K12 CA090628-09, K12 CA090628] Funding Source: Medline
Ask authors/readers for more resources
Purpose of review Autologous stem cell transplantation (SCT) has been an integral part of the management of multiple myeloma, especially for younger patients. During the past decade, several highly effective therapies have become available for treatment of myeloma, raising questions about the role of SCT for its management. This review focuses on recent findings in the context of previous studies demonstrating a benefit for SCT compared with conventional therapies. Recent findings Recent clinical trials have primarily focused on improving patient outcome by integrating the novel agents into various stages of myeloma therapy, including initial therapy resulting in improvement of disease control at the time of SCT, incorporation into conditioning regimens and finally, using maintenance approaches to prolong the response from SCT. In addition, recent trials also have demonstrated a potential role for tandem SCT in selected patients. However, the role of allogeneic SCT still remains to be better defined. Summary Patients with myeloma have more effective choices for therapy today and better outcome. Recent and ongoing trials will allow better selection of therapy, preferably in an individualized fashion, potentially translating into prolonged survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available